FdaApplication
BLA 761115
Identifiers
- fda_app_no: BLA761115
Properties
| Property | Value |
|---|---|
| applicant_name | Gilead Sciences, Inc. |
| application_type | BLA |
| approval_date | 2020-04-22 |
Revenue by product
TRODELVY
| Period | Revenue |
|---|---|
| Q2 2026 | $457.0M |
| Q1 2026 | $402.0M |
| Q4 2025 | $384.0M |
| Q3 2025 | $357.0M |
| Q2 2025 | $364.0M |
| Q1 2025 | $293.0M |
| Q4 2024 | $355.0M |
| Q3 2024 | $332.0M |
| Q2 2024 | $320.0M |
| Q1 2024 | $309.0M |
| Q4 2023 | $299.0M |
| Q3 2023 | $283.0M |
| Q2 2023 | $260.0M |
| Q1 2023 | $222.0M |
| Q4 2022 | $195.0M |
| Q3 2022 | $180.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRODELVY | SACITUZUMAB GOVITECAN-HZIY | 180MG | For Injection |
1 product